A tumor marker that guides chemo use mostly stays the same when glioma comes back
Original title: Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked at tumor samples and records from real patients, but it did not test a treatment.
The short version
For most people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary came back, a key tumor test result did not change.
What was studied. Researchers looked at tumor samples taken twice from 426 people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary came back. They checked a tumor marker called MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary, which helps doctors guess if the chemo drug temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary will work. They also looked at records from a smaller group of 27 people to see how the marker affected treatment choices.
What they found. The MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary result stayed the same in 84% of tumors when the cancer came back. It changed in 16%. Most of these changes were in tumors whose first result was close to the line between the two groups. In the smaller group, doctors more often tried temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary again when the tumor still had the marker.
What this means, and what it doesn't
What it could mean: If your glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary comes back, it may help to test the MGMT promoter methylation: MGMT is a gene whose protein repairs damage to a tumor's DNA. Methylation turns it down. Your report says how much, and your team uses that when they choose chemotherapy. The line between high and low is not settled. See the glossary marker again. A test that gives an exact amount, not just yes or no, may help you and your doctor decide whether to try temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary again.
What it doesn't mean: This study looked back at past records. It did not test a new treatment. It does not prove that a second round of temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary will help. It is not a cure, and it does not change care on its own. Talk with your care team about what testing makes sense for you.
Source: PubMed, September 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.